CD19靶向CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤疗效和安全性的Meta分析

李碧云; 韩亚辉; 殷楚云; 王颖超

doi:10.6039/j.issn.1001-0408.2022.21.18

您当前的位置：

首页 >

文章列表页 >

CD19靶向CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤疗效和安全性的Meta分析

循证药学 | 更新时间：2023-02-22

- CD19靶向CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤疗效和安全性的Meta分析
- Efficacy and safety of CD19-targeted CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma： a meta-analysis
- 中国药房 2022年33卷第21期页码：2660-2665
- 作者机构：
  
  1.郑州大学第一附属医院小儿内科，郑州　450052
  2.郑州大学第一附属医院小儿外科，郑州　450052
- 作者简介：
  
  硕士研究生。研究方向：小儿血液肿瘤。E-mail：961673569@qq.com
  主任医师，教授，硕士生导师，博士。研究方向：小儿血液肿瘤。E-mail：13838520369@163.com
- 基金信息：
  
  Δ 基金项目河南省医学科技攻关计划省部共建项目(SBGJ202002115)
- DOI：10.6039/j.issn.1001-0408.2022.21.18
  中图分类号： R979.1;R733.1
- 纸质出版日期：2022-11-15，
  
  收稿日期：2022-05-23，
  
  修回日期：2022-09-15，
扫描看全文
李碧云,韩亚辉,殷楚云等.CD19靶向CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤疗效和安全性的Meta分析 ^Δ[J].中国药房,2022,33(21):2660-2665.

LI Biyun,HAN Yahui,YIN Chuyun,et al.Efficacy and safety of CD19-targeted CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma： a meta-analysis[J].ZHONGGUO YAOFANG,2022,33(21):2660-2665.
李碧云,韩亚辉,殷楚云等.CD19靶向CAR-T治疗复发/难治性弥漫大B细胞淋巴瘤疗效和安全性的Meta分析 ^Δ[J].中国药房,2022,33(21):2660-2665. DOI： 10.6039/j.issn.1001-0408.2022.21.18.

LI Biyun,HAN Yahui,YIN Chuyun,et al.Efficacy and safety of CD19-targeted CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma： a meta-analysis[J].ZHONGGUO YAOFANG,2022,33(21):2660-2665. DOI： 10.6039/j.issn.1001-0408.2022.21.18.

摘要

目的

探讨CD19靶向嵌合抗原受体T细胞（CAR-T）治疗复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的疗效及其不良反应，为更加合理、高效地应用CAR-T提供循证依据。

方法

检索PubMed、Embase、Cochrane、ClinicalTrials.gov、中国知网、万方数据库、维普网并筛选从建库至2022年4月公开发表的CD19靶向CAR-T治疗R/R DLBCL的文献。以客观缓解率（ORR）、完全缓解率（CRR）和不良反应发生率作为结局指标，根据CAR-T细胞共刺激因子及研究类型的不同进行亚组分析，采用R 4.1.2软件进行Meta分析、敏感性分析和发表偏倚分析。

结果

共筛选出11篇文献，共计1 466名患者。CD19靶向CAR-T细胞治疗R/R DLBCL的ORR为72.1%（95%CI：62.3%～81.9%），CRR为50.8%（95%CI：41.1%～60.5%），细胞因子释放综合征（CRS）发生率为77.5%（95%CI：65.6%～89.4%），神经毒性发生率为41.4%（95%CI：26.8%～56.1%）。亚组分析结果显示：共刺激因子CD28亚组患者的ORR、CRR、CRS发生率及神经毒性发生率均高于4-1BB亚组，观察性试验亚组患者的ORR、CRR、CRS发生率及神经毒性发生率均高于干预性试验亚组。

结论

CD19靶向CAR-T治疗R/R DLBCL具有较高的ORR、CRR，同时也具有较高的不良反应发生率。共刺激因子CD28亚组患者与4-1BB亚组相比，有更高的ORR、CRR、CRS发生率和神经毒性发生率。

Abstract

OBJECTIVE

To investigate the efficacy and adverse reaction of CD19-targeted chimeric antigen receptor T cells （CAR-T） in the treatment of relapsed/refractory diffuse large B-cell lymphoma （R/R DLBCL）， so as to provide an evidence-based basis for more reasonable and efficient application of CAR-T.

METHODS

Retrieved from PubMed， Embase， Cochrane， ClinicalTrials.gov， CNKI， Wanfang， VIP database， the literature about CD19 targeted CAR-T in the treatment of R/R DLBCL that were published from the inception to April 2022 were screened. Taking objective remission rate （ORR）， complete remission rate （CRR） and incidence of adverse reactions as outcome indicators， subgroup analysis was performed according to the costimulatory factor of CAR-T and the different types of research. R 4.1.2 software was used for meta-analysis， sensitivity analysis and publication bias analysis.

RESULTS

A total of 11 pieces of literature were screened， involving 1 466 patients. The ORR of CD-19 targeted CAR-T cells in the treatment of R/R DLBCL was 72.1%（95% CI：62.3%-81.9%）， the CRR was 50.8%（95% CI：41.1%-60.5%）， the incidence of cytokine release syndrome （CRS） was 77.5%（95% CI：65.6%-89.4%）， the incidence of neurotoxicity was 41.4%（95% CI：26.8%-56.1%）. Results of subgroup analysis showed that the incidence of ORR， CRR， CRS and neurotoxicity in costimulatory factor CD28 subgroup were higher than those in 4-1BB subgroup. The incidence of ORR， CRR， CRS and neurotoxicity in the observational experimental subgroup were higher than those in the intervention experimental subgroup.

CONCLUSIONS

CD19 targeted CAR-T has high ORR and CRR for R/R DLBCL， as well as higher incidence of adverse reactions. Co-stimulatory factor CD28 has higher ORR， CRR， CRS incidence and neurotoxicity incidence than 4-1BB.

关键词

弥漫大B细胞淋巴瘤CD19复发/难治性嵌合抗原受体T细胞Meta分析

Keywords

CD19relapsed/refractorychimeric antigen receptor T cellsmeta-analysis

references

DI Y，YE J J，ZHANG B L. Systemic diffuse large B-cell lymphoma with bilateral ciliary body involvement[J]. Chin Med J （Engl），2020，133（1）：109-110.

LIANG Y，LIU H，LU Z M，et al. CD19 CAR-T expres- sing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies[J]. J Hematol Oncol，2021，14（1）：26.

KERSTEN M J，SPANJAART A M，THIEBLEMONT C. CD19-directed CAR T-cell therapy in B-cell NHL[J]. Curr Opin Oncol，2020，32（5）：408-417.

ROEX G，TIMMERS M，WOUTERS K，et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma[J]. J Hematol Oncol，2020，13（1）：164.

WESTIN J R，KERSTEN M J，SALLES G，et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas：observations from the JULIET，ZUMA-1，and TRANSCEND trials[J]. Am J Hematol，2021，96（10）：1295-1312.

BACHANOVA V，TAM C S，BORCHMANN P，et al. Impact of tisagenlecleucel chimeric antigen receptor （CAR）-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma （r/r DLBCL）[J]. Blood，2019，134：242.

SLIM K，NINI E，FORESTIER D，et al. Methodological index for non-randomized studies （minors）：development and validation of a new instrument[J]. ANZ J Surg，2003，73（9）：712-716.

BALDUZZI S，RÜCKER G，SCHWARZER G. How to perform a meta-analysis with R：a practical tutorial[J]. Evid Based Ment Health，2019，22（4）：153-160.

ABRAMSON J S，PALOMBA M L，GORDON L I，et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas （TRANSCEND NHL 001）：a multicentre seamless design study[J]. Lancet，2020，396（10254）：839-852.

BISHOP M R，DICKINSON M，PURTILL D，et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma[J]. N Engl J Med，2022，386（7）：629-639.

FARAMAND R，JAIN M，STAEDTKE V，et al. Tumor microenvironment composition and severe cytokine release syndrome （CRS） influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel[J]. Clin Cancer Res，2020，26（18）：4823-4831.

IACOBONI G，VILLACAMPA G，MARTINEZ-CIBRIAN N，et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma[J]. Cancer Med，2021，10（10）：3214-3223.

LOCKE F L，GHOBADI A，JACOBSON C A，et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma （ZUMA-1）：a single-arm，multicentre，phase 1-2 trial[J]. Lancet Oncol，2019，20（1）：31-42.

LOCKE F L，MIKLOS D B，JACOBSON C A，et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma[J]. N Engl J Med，2022，386（7）：640-654.

NASTOUPIL L J，JAIN M D，FENG L，et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma：results from the US lymphoma CAR T consortium[J]. J Clin Oncol，2020，38（27）：3119-3128.

NEELAPU S S，DICKINSON M，MUNOZ J，et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma：the phase 2 ZUMA-12 trial[J]. Nat Med，2022，28（4）：735-742.

PINNIX C C，GUNTHER J R，DABAJA B S，et al. Brid- ging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma[J]. Blood Adv，2020，4（13）：2871-2883.

SCHUSTER S J，TAM C S，BORCHMANN P，et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas （JULIET）：a multicentre，open-label，single-arm，phase 2 study[J]. Lancet Oncol，2021，22（10）：1403-1415.

WUDHIKARN K，PALOMBA M L，PENNISI M，et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma[J]. Blood Cancer J，2020，10（8）：79.

WANG L，LI L R，YOUNG K H. New agents and regimens for diffuse large B cell lymphoma[J]. J Hematol Oncol，2020，13（1）：175.

STERNER R C，STERNER R M. CAR-T cell therapy：current limitations and potential strategies[J]. Blood Cancer J，2021，11（4）：69.

KOCHENDERFER J N，DUDLEY M E，KASSIM S H，et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor[J]. J Clin Oncol，2015，33（6）：540-549.

JUNE C H，SADELAIN M. Chimeric antigen receptor therapy[J]. N Engl J Med，2018，379（1）：64-73.

ROBERTS Z J，BETTER M，BOT A，et al. Axicabtagene ciloleucel，a first-in-class CAR T cell therapy for aggressive NHL[J]. Leuk Lymphoma，2018，59（8）：1785-1796.

BRUDNO J N，KOCHENDERFER J N. Recent advances in CAR T-cell toxicity：mechanisms，manifestations and management[J]. Blood Rev，2019，34：45-55.

WUDHIKARN K，PENNISI M，GARCIA-RECIO M，et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality[J]. Blood Adv，2020，4（13）：3024-3033.

WANG W X，JIANG J T，WU C P. CAR-NK for tumor immunotherapy：clinical transformation and future pro- spects[J]. Cancer Lett，2020，472：175-180.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

伊伐布雷定对冠心病患者血管内皮功能影响的Meta分析

ADRB1 Arg389Gly多态性对比索洛尔疗效影响的Meta分析

阿司匹林对比其他抗凝剂预防骨科术后血栓栓塞有效性和安全性的Meta分析

布拉氏酵母菌对比双歧杆菌三联活菌治疗儿童腹泻有效性和安全性的Meta分析

全球血友病患者健康效用值的系统综述与Meta分析